Jove
Visualize
Contact Us

Related Experiment Videos

AMPA receptor antagonists.

S S Nikam1, B E Kornberg

  • 1Deparment of Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. SHAM.NIKAM@WL.COM

Current Medicinal Chemistry
|February 15, 2001
PubMed
Summary

AMPA receptor antagonists show promise for neuroprotection but face challenges with physical properties. Research focuses on developing selective antagonists and improving drug candidates for neurological disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivatives.

Journal of medicinal chemistry·1999
Same author

Synthesis and biological evaluation of substituted 4-(OBz)phenylalanine derivatives as novel N-type calcium channel blockers.

Bioorganic & medicinal chemistry letters·1999
Same author

The zinc finger transcription factor Zif268/Egr-1 is essential for Schwann cell expression of the p75 NGF receptor.

Molecular and cellular neurosciences·1995
Same author

Renin inhibitors containing alpha-heteroatom amino acids as P2 residues.

Journal of medicinal chemistry·1992
Same author

Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.

Journal of medicinal chemistry·1992
Same author

Effects of structural changes in the dsdA-dsdC intergenic region on D-serine deaminase synthesis.

Journal of bacteriology·1991
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • AMPA receptor antagonists are a class of excitatory amino acid receptor antagonists.
  • They have demonstrated significant neuroprotective effects in models of cerebral ischemia and neuronal injury.
  • Poor physicochemical properties have hindered their development as therapeutic agents.

Purpose of the Study:

  • To review the development and challenges of AMPA receptor antagonists.
  • To discuss structure-activity relationships (SAR) and pharmacophore models for competitive antagonists.
  • To explore strategies for designing selective AMPA receptor antagonists and non-competitive modulators.

Main Methods:

  • Review of existing literature on AMPA receptor antagonists.
  • Analysis of structure-activity relationships (SAR) from various compound series.
  • Discussion of drug design efforts by pharmaceutical companies.

Main Results:

  • The quinoxaline-2,3-dione scaffold is central to many competitive antagonists (e.g., NBQX, ZK200775).
  • Selective AMPA antagonists with high affinity have been developed by minimizing NMDA-GlyN receptor interactions.
  • Non-competitive antagonists, particularly negative allosteric modulators like GYKI 52466, show improved physical properties but limited in vitro activity.

Conclusions:

  • Despite challenges, AMPA receptor antagonists hold potential for treating neurological disorders.
  • Ongoing research focuses on optimizing selectivity, potency, and drug-like properties.
  • Newer compound classes like phthalazines and quinazolines offer promise for next-generation therapeutics.

Related Experiment Videos